IN8bio Inc. (NASDAQ:INAB) shares received a positive update from Jones Trading as analyst Soumit Roy upgraded the company's stock rating from Hold to Buy. Along with the rating change, Roy established ...
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February ...
IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up ...
IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...
February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma ...
Use this link to participate or access the listen-only version of the webcast here NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company ...
纽约 - 专注于伽马-德尔塔T细胞疗法的生物制药公司IN8bio, Inc. (Nasdaq: ...
周二，Jones Trading分析师Soumit Roy将IN8bio Inc. (NASDAQ: INAB )的股票评级从持有上调至买入。同时，Roy为IN8bio设定了1.20美元的新目标价。根据InvestingPro数据显示，三位分析师最近上调了其盈利预期，目标价区间在1.50美元至8.00美元之间，相对当前0.32美元的股价显示出显著的上涨潜力。
IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback